Daily briefing: Funding calls plummet as NIH turns away from agency-directed science
Summary
The US National Institutes of Health (NIH), the world’s largest biomedical funder, is shifting away from issuing targeted funding calls (NOFOs) that ask researchers to address specific scientific problems. Instead, it is prioritising ‘unsolicited’, investigator-initiated proposals driven by scientists’ own interests. The NIH argues this reduces administrative overhead and gives researchers more freedom. Critics warn the move centralises decision-making, hands more power to political appointees and programme directors, and may reduce coordinated, large-scale projects and attention to neglected areas.
Key Points
- NIH has sharply reduced the number of agency-directed funding calls (NOFOs), with data showing about a 90% drop compared with the previous 13-year average.
- The agency is emphasising unsolicited, investigator-driven proposals rather than inviting applications for specific priorities or coordinated programmes.
- Funding decisions will increasingly require sign-off from political appointees rather than relying solely on panels of independent scientists and programme staff stewardship.
- NIH says the change will cut administration costs and increase researcher flexibility; opponents argue it risks centralised control and the loss of long-term scientific stewardship.
- Potential consequences include fewer large collaborative initiatives (for example, big-science projects like the Human Genome Project), widening knowledge gaps for neglected diseases and underserved populations, and altered career trajectories for researchers who depend on predictable, targeted funding streams.
Context and relevance
This is a policy-level change with wide-reaching effects across biomedical research. Funding mechanisms shape what science gets done: targeted calls can drive coordinated efforts, rapid responses and equity-focused research, while investigator-led grants favour curiosity-driven work and individual innovation. The NIH’s move reflects broader debates about centralised control, political oversight of science funding and how to balance efficiency with strategic stewardship. If you work in biomedical research, fund administration, clinical translation or research strategy, this change affects grant planning, collaborations and research priorities.
Why should I read this?
Short version: if you apply for NIH grants, run projects that rely on coordinated funding, or care about which areas get prioritised, this matters big time. It’s not just bureaucratic fiddling—it could rewrite how big projects get funded and who gets attention (and cash).
Author’s take (punchy): This is a tectonic shift in how the biggest biomedical funder calls the shots. Read the detail if you want to stay ahead of changes that will ripple through labs, collaborations and research careers.